Core Insights - BioPorto A/S has announced a business strategy update, outlining its "Forward" strategic direction and aspirations towards 2028, with a focus on achieving cash flow positivity by the second half of 2027 [1][10] Strategic Direction - The "Forward" plan is a three-year strategy aimed at improving kidney health through actionable biomarkers, with a goal to transform kidney care globally [2] - The plan includes building market adoption, capturing high growth, and expanding the addressable market [2] Aspirations Towards 2028 - The company aims to be cash flow positive in the second half of 2027, requiring DKK 60-70 million in funding [10] - Revenue expectations for FY 2028 are set between DKK 150-200 million, with an adjusted EBITDA margin of at least 15% [9][16] Market Adoption Goals - By the end of 2026, BioPorto aims to have over 60 active hospitals in the US and reach 100 active hospitals globally by the end of 2027 [5][7] - The company plans to expand its market penetration in both pediatric and adult segments, leveraging enhanced clinical guidelines [7] Commercialization Strategy - BioPorto will focus on securing strategic partnerships with instrument manufacturers to drive product adoption and facilitate faster laboratory utilization of its biomarkers [5] - The company is preparing for EU IVDR certification, expected in 2027, to support its European market growth [6] Product Development and Market Expansion - The company intends to broaden its product portfolio to address additional clinical settings relevant to the NGAL biomarker, with a goal of having over 170 active hospitals globally by the end of 2028 [8]